Find trials
Consejos para buscar

Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnancies (VANISH)

Overview

Información sobre este estudio

Panorama® is a commercially available Laboratory Developed Test (LDT) certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Panorama analyzes SNPs to distinguish maternal from fetal (placental) DNA, targeting 13,932 SNPs covering chromosomes 21, 18, 13, X and Y, to determine chromosomal abnormalities and fetal sex. Panorama is used in twin pregnancies to screen for a variety of abnormalities, including trisomies 21, 18 and 13, monosomy X zygosity and fetal sex for each twin.

The primary objectives of this study are to use the Panorama® testing to:
1) Develop a new algorithm and methodology that will distinguish between the non-viable or demised twin and the living twin in dizygotic twins with a single living twin..
2) Assess the accuracy of the new algorithm to determine which of the signals in the Panorama samples correspond to the living twin versus the non-viable or demised twin. .

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Female age 18 or older at the time of signing informed consent.
  • Ultrasound confirmation of singleton pregnancy.
  • GA ≥ 9 weeks at the time of first sample collection.
  • Willing and able to provide written informed consent.
  • Willing and able to comply with study procedures, including blood sample and neonatal buccal swab.
  • Cohort 1: Ultrasound confirmation of VT Pregnancies:
    • Ultrasound confirmation of VT;
    • Spontaneous fetal demise of one twin or empty sac.
  • Cohort 2: High Risk for VT Pregnancies:
    • Panorama yielding “high risk for twin/VT/triploidy” result;
    • Ultrasound confirmation of single gestation;
    • No evidence of triploidy.

Exclusion Criteria:

  • Known monozygotic twin pregnancy.
  • Multiple gestation.
  • VT pregnancy resulting from iatrogenic fetal demise.
  • GA < 9 weeks.
  • Evidence of triploidy other than Panorama test results.
  • Any confounding complication or condition that, in the opinion of the investigators, precludes participation in the study; this may include a cancer diagnosis, organ transplant, pregnancy utilizing an egg donor, or other findings that may interfere with interpretation of Panorama results.

Eligibility last updated 10/19/21. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Myra Wick, M.D., Ph.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available

Otros temas en investigación

.
CLS-20527711

Mayo Clinic Footer